Compare Brown-Forman Corporation Class B (BF.B) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs GSK plc — how do they compare? Brown-Forman Corporation Class B trades at $27.99, while GSK plc trades at $50.4 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while Brown-Forman Corporation Class B pays none. Which is the better fit depends on your goals.
| BF.B | GSK | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $61.18 |
52-Week Low | $22.80 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $28.19, down 1.16% for the day, with technical indicators showing a bullish trend supported by moving averages. The stock has demonstrated strong earnings performance, beating expectations in three of the last four quarters. Analyst sentiment is mixed with a 25% buy rating amid limited recent news coverage.
The outlook remains cautiously optimistic given recent earnings strength, though the divided analyst consensus and lack of current financial metrics present valuation challenges. Key risks include execution consistency and market volatility, while institutional positioning will be critical for sustained momentum.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
